Nexus Company Profile
What is the competitive landscape for NEXUS
NEXUS has twenty-four approved drugs.
There are five US patents protecting NEXUS drugs. There is one tentative approval on NEXUS drugs.
Summary for Nexus
| US Patents: | 5 |
| Tradenames: | 26 |
| Ingredients: | 23 |
| NDAs: | 24 |
| Patent Litigation for Nexus: | See patent lawsuits for Nexus |
| PTAB Cases with Nexus as petitioner: | See PTAB cases with Nexus as petitioner |
Drugs and US Patents for Nexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-002 | Feb 28, 2023 | RX | Yes | Yes | 11,571,398 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | AP1 | RX | Yes | Yes | 11,090,278 | ⤷ Start Trial | ⤷ Start Trial | |||
| Nexus | STERILE WATER FOR INJECTION | sterile water for injection | LIQUID;N/A | 217536-002 | Jul 11, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20220009985 | ⤷ Start Trial |
| South Korea | 20240096847 | ⤷ Start Trial |
| South Korea | 102675027 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340828 | LUC00195 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
| 0478363 | C990040 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TIROFIBAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN HYDRAAT, IN HET BIJZONDER TIROFIBANHY- DROCHLORIDE MONOHYDRAAT; NATL REGISTRATION NO/DATE: RVG 23380-1 19990707; FIRST REGISTRATION: DE 42618.00.00-01 19980630 |
| 1856135 | LUC00153 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
